| [1] |
Parkin DM,Bray F,Ferlay J,et al.Gobal cancer statistics,2002[J].CA Cancer J Clin,2005,55(2):74-108.
|
| [2] |
刘洋,田欣,吴荣,等.戈舍瑞林联合依西美坦治疗绝经前及围绝经期复发转移性乳腺癌的疗效分析[J]. 实用药物与临床,2014,(11):1435-1438,1439.
|
| [3] |
Landis SH,Murray T,Bolden S,et al. Cancer Statistics,1999[J]. CA cancer J Clin,1999,49(1):8-31.
|
| [4] |
Greenberg PA,Hortobagyi GN,Smith TL,et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer[J].J Clin Oncol,1996,14(8):2197-2205.
|
| [5] |
徐兵河.乳腺癌综合治疗进展[J].临床药物治疗杂志,2006,4(2):16-21.
|
| [6] |
孙建伟,纳志明,贾玲.乳腺癌的内分泌治疗及研究进展[J]. 云南医药,2006,27(2):173-178.
|
| [7] |
刘彩刚,李学璐,马振海. 晚期乳腺癌的非手术治疗进展[J]. 医学与哲学,2014,35(8B):21-23.
|
| [8] |
王俊斌,郑荣生.乳腺癌新辅助内分泌治疗研究进展[J].蚌埠医学院学报,2009,34(11):1048-1050.
|
| [9] |
范嘉躜,杨振宇,曾涛.GnRH 类似物在乳腺癌治疗中的应用和卵巢功能保护[J]. 上海医药,2012,33(19):22-24.
|
| [10] |
吴三纲,何振宇,郭君,等.戈舍瑞林联合内分泌药物治疗绝经前晚期乳腺癌的临床研究[J]. 中国癌症杂志,2011,21(8):626-631.
|
| [11] |
MathewA, Davidson NE.Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer[J]. Breast,2015,24(S2):S120-125.
|
| [12] |
Pagani O,Regan MM,Walley BA, et al. Adjuvant exemestane ovarian suppresion in premenopausal breast cancer[J]. N Engl Med,2014,371(2):107-118.
|
| [13] |
Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase Ⅲstudy of the international letrozole breast cancer group. J Clin Oncol, 2001(10),19:2596-2606.
|
| [14] |
Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate[J]. J Clin Oncol, 1998,16(2):453-461.
|
| [15] |
Ebrahim H.Endocrine therapy in metastatic breast cancer:a closer look at the current clinical practice[J].J Community Support Oncol,2015,13(10):356-361.
|
| [16] |
Kaufmann M, Bajetta E,Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced b reast cancer:results of a phase Ⅲrandomized double-blind trial.The Exemestane Study Group[J]. J Clin Oncol, 2000, 18(7):1399-1411.
|
| [17] |
Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer[J]. J Clin Oncol,2010,28(30):4594-4600.
|
| [18] |
Mehta RS,Barlow WE,Albain KS,et al. Combination anastrozole and fulvestrant in metastatic breast cancer [J]. N Engl J Med,2012,367(5):435-444.
|
| [19] |
Ghayad SE,Vendrell JA,Ben Larbi S,et al. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed byinhibiting MAPK or PI3K /Akt signaling pathways[J].Int J Cancer,2010,126(2):545-562.
|
| [20] |
Miller TW, Hennessy BT, González-Angulo AM, et al.Hyperactivation of phosphatidylinositol- 3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer[J]. J Clin Invest,2010,120(7):2406-2413.
|
| [21] |
Yue W, Fan P, Wang J, et al. Mechanisms of acquired resistance toendocrine therapy in hormone-dependent breast cancer cells[J]. J Steroid Biochem Mol Biol,2007,106(1-5):102-110.
|
| [22] |
王昕怡,张珍,邵加庆,等.乳腺癌的内分泌治疗新进展[J].中国全科医学,2012,15 (9):959-962.
|
| [23] |
Jelovac D,Sabnis G,Long BJ,et al. Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole[J].Cancer Res,2005,65(12):5380-5389.
|
| [24] |
Chumsri S,Howes T,Bao T,et al. Aromatase,aromataseinhibitors,and breast cancer[J].J Steroid Biochem Mol Biol,2011,125(1/2):13-22.
|
| [25] |
Miller TW,Hennessy BT,González-Angulo AM,et al.Hyperactivation of phosphatidylinositol- 3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer[J]. J Clin Invest,2010,120(7):2406-2413.
|
| [26] |
Yue W,Fan P,Wang J,et al. Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells[J]. J Steroid Biochem Mol Biol,2007,106 (1/5):102-110.
|
| [27] |
Boulay A, Rudloff J, Ye J, et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models ofbreast cancer[J].Clin Cancer Res,2005,11(14):5319-5328.
|
| [28] |
Beeram M, Tan QT, Tekmal RR, et al. Akt-induced endocrinetherapy resistance is reversed by inhibition of mTOR signaling[J]. Ann Oncol,2007,18(8):1323-1328.
|
| [29] |
TanakaC, O'ReillyT, Kovarik JM, et al. Identifying optimalbiologic doses of everolimus (RAD001) in patients withcancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data[J]. J ClinOncol,2008,26(10):1596-1602.
|
| [30] |
Schwartz GK,Lorusso PM,Dickson MA,et al. Phase I study of PD 0332991,a cyclin-dependent kinase inhibitor,administered in 3-week cycles (Schedule 2/1)[J].Br J Cancer,2011,104 (12):1862-1868.
|
| [31] |
Britton DJ, Hutcheson IR, Knowlden JM, et al. Bidirectional cross talk between ERalpha and EGFR signalling pathways tamoxifenresistant growth [J]. Breast Cancer Res Treat,2006,96(2):131-146.
|